Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, Wedgewood Composite’s net return was 5.

Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer Perform to Underperform. Analyst Price Forecast Suggests 14.75% Upside As of December 23,

Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust. The company maintains robust financial health with a current ratio of 3.

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter Aortic Valve Replacement (TAVR).